安罗替尼联合伊立替康二线治疗小细胞肺癌临床效果研究

Clinical efficacy of anlotinib combined with irinotecan second line in patients with small cell lung cancer

目的探讨安罗替尼联合伊立替康二线在小细胞肺癌(Small cell lung cancer,SCLC)治疗中的临床应用效果。方法选取2018年1月—2020年2月在南阳市中心医院接受治疗的120例SCLC患者进行研究,经随机数字表法分组。对照组(60例)给予患者拓扑替康治疗,观察组(60例)给予患者安罗替尼和伊立替康治疗,对比分析两组患者的临床治疗效果、T细胞亚群指标水平、肿瘤标志物指标水平、不良反应发生率及疾病控制率。结果观察组客观缓解率为96.67%,高于对照组的86.67%,差异有统计学意义(P<0.05);与对照组和治疗前对比,观察组治疗后的CD4、CD8、CD4/CD8水平明显降低;与对照组比较,观察组治疗后癌胚抗原(CEA)、神经特异性烯醇化酶(NSE)、鳞状细胞癌抗原(SCC)水平更低;治疗后观察组患者的不良反应发生率8.3%,低于对照组的5.00%,但无统计学意义(P>0.05),观察组疾病控制率93.33%,高于对照组的80.00%(P<0.05)。结论联合应用安罗替尼与伊立替康对小细胞肺癌患者开展二线治疗,可有效改善患者的免疫功能,缓解其病情,避免患者病情加重,不良反应可耐受,有助于进一步提高患者的临床治疗效果。

Objective To investigate the clinical effect of anlotinib combined with irinotecan second line in the treatment of small cell lung cancer(SCLC).Methods A total of 120 patients with SCLC who received treatment in our hospital from January 2018 to February 2020 were selected for this study,and were grouped by random number table method.The control group(60 cases)was treated with topotecan,and the observation group(60 cases)was treated with amrotinib and irinotecan.The clinical treatment effect,T cell subsets,tumor marker levels,incidence of adverse reactions and disease control rate of the two groups were compared and analyzed.Results The objective remission rate in the observation group was 96.67%,higher than 86.67%in the control group(P<0.05).Compared with the control group and before treatment,the levels of CD4,CD8 and CD4/CD8 in the observation group were lower after treatment.Compared with the control group,CEA,NSE and SCC levels were lower in the observation group after treatment.After treatment,the incidence of adverse reactions in the observation group was 8.3%,lower than that in the control group(5.00%),but there was no statistical significance(P>0.05).The disease control rate in the observation group was 93.33%,higher than that in the control group(80.00%)(P<0.05).Conclusion Combined application of amrotinib and irinotecan in the second-line treatment of patients with small cell lung cancer can effectively improve the immune function of patients,alleviate their disease,avoid the exacerbation of patients’disease,and help to further improve the clinical treatment effect of patients.